MTHFR、GSTP1基因多态性与Ⅲ期结肠癌术后FOLFOX4辅助化疗敏感性及预后的关系  

Association of MTHFR and GSTP1 gene polymorphisms with the sensitivity and prognosis of FOLFOX4 adjuvant chemotherapy after surgery for stageⅢcolon cancer

作　　者：赵帅[1] 闫海洋 陈静[1] 魏从真[1] 金素丽 孙静娜[1] 郭英[2] 刘佳佳[1] ZHAO Shuai;YAN Hai-yang;CHEN Jing;WEI Cong-zhen;JIN Su-li;SUN Jing-na;GUO Ying;LIU Jia-jia(Inspection Center,First Hospital of Hebei Medical University,Shijiazhuang,Hebei 050031,China;不详)

机构地区：[1]河北医科大学第一医院检验中心,河北石家庄050031 [2]河北医科大学第一医院肿瘤科,河北石家庄050031

出　　处：《中国临床研究》2022年第11期1528-1532,共5页Chinese Journal of Clinical Research

基　　金：河北省卫生健康委科研基金项目(20190481)。

摘　　要：目的分析亚基四氢叶酸还原酶(MTHFR)、谷胱甘肽S转移酶P1(GSTP1)基因多态性与Ⅲ期结肠癌术后FOLFOX4辅助化疗敏感性及预后的关系,为临床治疗提供参考。方法选取河北医科大学第一医院2017年3月至2019年1月收治的Ⅲ期结肠癌术后接受FOLFOX4辅助化疗患者84例作为研究对象,检测患者的MTHFR-rs1801131、GSTP1-rs1695基因多态性,对患者术后随访3年,分析MTHFR、GSTP1不同基因多态性与术后FOLFOX4辅助化疗敏感性及3年生存率的相关性。结果84例患者MTHFR-rs1801131基因型AA型占78.57%,AC型占11.90%,CC型占9.52%,GSTP1-rs1695基因型AA型占51.19%,AG型占38.10%,GC型占10.71%。MTHFR-rs1801131基因型AA型、AC/CC型的患者化疗敏感性比较差异无统计学意义(21.21%vs 27.78%,χ^(2)=0.074,P=0.783)。GSTP1-rs1695基因型AG/GC型与AA型相比化疗敏感性较高(46.34%vs 18.60%,χ^(2)=7.403,P=0.007)。MTHFR-rs1801131基因型AC/CC型的随访3年生存率低于AA型(11.11%vs 84.85%,P<0.01)。结论GSTP1-rs1695基因型为AG/GC型Ⅲ期结肠癌术后FOLFOX4辅助化疗敏感性较高,MTHFR-rs1801131基因型AA型可保证Ⅲ期结肠癌术后FOLFOX4辅助化疗后获得更好的预后及生存率。Objective To explore and analyze the relationship between subunit tetrahydrofolate reductase(MTHFR),glutathione S-transferase P1(GSTP1)gene polymorphisms and the sensitivity and prognosis of FOLFOX4 adjuvant chemotherapy after surgery for stageⅢcolon cancer.Methods Eighty-four patients with stageⅢcolon cancer who received FOLFOX4 adjuvant chemotherapy after operation in First Hospital of Hebei Medical University from March 2017 to January 2019 was selected as the research objects.MTHFR-rs1801131 and GSTP1-rs1695 gene polymorphisms of patients were detected.The patients were followed up for 3 years after operation.The correlation between different gene polymorphisms of MTHFR and GSTP1 and postoperative FOLFOX4 adjuvant chemotherapy sensitivity and 3-year survival rate was analyzed.Results The distribution of MTHFR-rs1801131 genotypes was as follows:AA type accounted for 78.57%,AC type accounted for 11.90%,CC type accounted for 9.52%,GSTP1-rs1695 genotype AA type accounted for 51.19%,AG type accounted for 38.10%,GC type accounted for 10.71%.There was no significant difference in chemosensitivity between AA genotype and AC/CC genotype patients with MTHFR-rs1801131 genotype(21.21%vs 27.78%,χ^(2)=0.074,P=0.783).The GSTP1-rs1695 patients of AG/GC genotype,was more sensitive to chemotherapy than that of AA genotype(46.34%vs 18.60%,χ^(2)=7.403,P=0.007).The 3-year survival rate of MTHFR-rs1801131 genotype AC/CC was significantly lower than that of AA type,the difference was statistically significant(11.11%vs 84.85%,P<0.01).Conclusion GSTP1-rs1695 genotype is AG/GC typeⅢcolon cancer with higher sensitivity to postoperative FOLFOX4 adjuvant chemotherapy,MTHFR-rs1801131 genotype AA can ensure better prognosis after postoperative FOLFOX4 adjuvant chemotherapy for stageⅢcolon cancer and survival rate.

关 键 词：亚基四氢叶酸还原酶 谷胱甘肽S转移酶P1 结肠癌 Ⅲ期 FOLFOX4 辅助化疗 

分 类 号：R735.3[医药卫生—肿瘤]